Compare UNF & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNF | DNTH |
|---|---|---|
| Founded | 1936 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.5B |
| IPO Year | 1994 | 2018 |
| Metric | UNF | DNTH |
|---|---|---|
| Price | $272.93 | $93.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $238.33 | $121.00 |
| AVG Volume (30 Days) | 218.4K | ★ 1.3M |
| Earning Date | 04-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.57% | N/A |
| EPS Growth | ★ 2.70 | N/A |
| EPS | ★ 3.02 | N/A |
| Revenue | ★ $1,696,489,000.00 | $2,036,000.00 |
| Revenue This Year | $3.69 | N/A |
| Revenue Next Year | $3.53 | $29.48 |
| P/E Ratio | $90.44 | ★ N/A |
| Revenue Growth | ★ 6.63 | N/A |
| 52 Week Low | $147.66 | $18.08 |
| 52 Week High | $283.77 | $98.70 |
| Indicator | UNF | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 62.30 | 58.81 |
| Support Level | $258.79 | $79.27 |
| Resistance Level | $282.14 | $96.50 |
| Average True Range (ATR) | 5.49 | 5.26 |
| MACD | 0.42 | 1.20 |
| Stochastic Oscillator | 98.03 | 79.76 |
UniFirst Corp provides uniform and workwear programs, facility management, and safety supplies and services across North America. It designs, manufactures, rents, cleans, and sells uniforms and protective clothing, including flame-resistant and high-visibility garments. It also offers industrial wiping products, floor mats, cleaning supplies, first aid cabinets, and fire protection services such as inspection and maintenance. Serving various industries, the company provides customized uniforms and specialized cleaning for nuclear and cleanroom facilities. It operates through three segments: Uniform & Facility Service Solutions, First Aid & Safety Solutions, and Other, with the majority of revenue from Uniform & Facility Service Solutions.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.